Alkermes plc: Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented

Related Keywords

New York ,United States ,Massachusetts ,Italy ,Athlone ,Westmeath ,Ireland ,Ohio ,Waltham ,Dublin ,Alex Braun ,Craig Hopkinson ,Marisa Borgasano ,Aripiprazole Lauroxil ,Behavioral Health System ,Research Databases ,Alkermes ,Schizophrenia International Research Society ,Ibm ,Research Development At Alkermes ,Department Of Psychiatry ,Nasdaq ,Icahn School Of Medicine At Mount Sinai ,Alkermes Inc ,Alkermes Pharma Ireland ,Results Presented From ,Early Phase ,Patients Early ,New York Assessment ,Adverse Cognitive Effects ,Neuropsychiatric Treatment ,Chief Medical Officer ,Executive Vice President ,Young Adults ,Schizophreniform Disorder ,Bipolari Disorder Who Are Early ,Their Illness ,Joseph Klingenstein Professor ,Icahn School ,Pharmaceutical Pipeline ,Poster Session ,Structured Benefit Risk Assessment ,Prescription Dispensing Patterns ,Real World Evidence ,Comorbidities Associated With Olanzapine ,Real World Data ,Patients With Schizophrenia ,Versus Caregiver ,Clinician Reports ,Cognitive Difficulties ,Schizophrenia Switching ,Post Hoc ,Prescribing Information ,Adverse Reactions ,Elderly Patients ,Dementia Related Psychosis ,Boxed Warning ,Severe Opioid Withdrawal ,Physiologically Dependent ,Life Threatening Opioid Overdose ,Malignant Syndrome ,Systemic Symptoms ,Motor Impairment ,Temperature Dysregulation ,Combination Treatment ,Mixed Episodes ,Including Stroke ,Medication Errors ,Diabetes Mellitus ,Temperature Regulation ,Observed Adverse Reactions ,Site Reactions ,Alkermes Pharma Ireland Limited ,Presents ,Data ,Rom ,Sychiatry ,Portfolio ,022 ,Congress ,Schizophrenia ,Nternational ,Research ,Society ,